Grace Therapeutics (NASDAQ:GRCE – Get Free Report) and PureTech Health (NASDAQ:PRTC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.
Volatility and Risk
Grace Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Grace Therapeutics and PureTech Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Grace Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| PureTech Health | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Grace Therapeutics and PureTech Health”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Grace Therapeutics | N/A | N/A | -$9.57 million | ($0.40) | -5.83 |
| PureTech Health | $4.66 million | 91.01 | -$109.74 million | N/A | N/A |
Grace Therapeutics has higher earnings, but lower revenue than PureTech Health.
Profitability
This table compares Grace Therapeutics and PureTech Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Grace Therapeutics | N/A | -15.58% | -14.51% |
| PureTech Health | N/A | N/A | N/A |
Insider & Institutional Ownership
6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Grace Therapeutics beats PureTech Health on 6 of the 10 factors compared between the two stocks.
About Grace Therapeutics
Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
